Welcome to the 12th World Clinical Biomarker & CDx Summit 2022

Your definitive end-to-end biomarker-driven & diagnostic-enabled drug development summit

Returning to its home-ground in Boston, the 12th World CB & CDx Summit is back at a pivotal time for precision medicine! Join your dedicated community as we explore biomarker discovery through to commercialization alongside a diagnostic to deliver safe and effective precision & targeted therapies to more patients with maximised global access.

Across 2 days and 3 tracks, 70+ diverse industry stakeholders will address the most important challenges, technological innovations and pipeline updates to support the community in bringing the next generation of Drug-Dx development to the hands of patients.

From next-generation biomarker discovery & validation, the latest clinical multi-biomarker & AI-based stratification strategies, advances in liquid biopsy validation through to critical U.S FDA CRRH & CDER, IVDR & APAC regulatory updates, you cannot afford to miss this crucial date in the precision medicine industry calendar in 2022.


Stay ahead of the biomarker and CDx adoption strategy curve and lay the foundation of a speedy approval and launch excellence to deliver a breakthrough therapy for patients worldwide!

Join Us to Meet Industry Trailblazers Sharing Cutting-Edge Developments Across Your Drug-Dx Development Timeline:

Plenary Stage

Updating the industry on current frameworks for biomarker & CDx development, applying regulatory body and biopharma insights to navigate global approvals with U.S FDA CDRH & CDER, TÜV SÜD & Loxo Oncology

Gold Track: Biomarker Discovery & Translational Development

Uncover tumor biology & leverage bioinformatic approaches to drive next-generation predictive biomarker discovery & validation with Bicycle Therapeutics, iOnctura, Leap Therapeutics & more

Red Track: Clinical Biomarker Development

Define your patient stratification strategy addressing complex multi-biomarker biology gaining learnings from Marengo Therapeutics, Takeda, Kronos Bio, H3 Biomedicine & more applying RWD, multi-omics, digital pathology & liquid biopsy

Blue Track: CDx Development & Commercialization

Explore the scope of 2022 CDx development with Janssen, Daiichi Sankyo, Regeneron & Vertex Pharmaceuticals and build the foundations for a competitive Drug-Dx launch

Gamechanger Solution & Service Providers

Keep a finger on the pulse of industry’s rapidly advancing technologies to fast-track biomarker discovery & patient stratification through identifying innovative partners in 2022